Exosome Skincare OEM & ODM Manufacturing in Korea

Exosome briefs are the ones where we most often have to slow a project down before speeding it up. The category sells well and the science is genuinely interesting, but the word "exosome" covers several materially different raw materials with completely different regulatory outcomes. Choosing the wrong one does not show up as a formulation problem — it shows up as a product that cannot be sold in your destination market.

What Is an Exosome?

Exosomes are extracellular vesicles: small membrane-bound particles, roughly 30 to 150 nanometres across, that cells release and that carry proteins, lipids and nucleic acids. In biology they are studied as a signalling mechanism between cells. In cosmetics the term is used more loosely, and that looseness is where projects go wrong.

Three quite different things are sold to brands under this heading:

• Plant-derived exosomes and exosome-like nanovesicles — isolated from plant material or plant callus culture. Common sources include Centella asiatica, rose, edelweiss and various fruit and root materials. This is the mainstream cosmetic route.
• Microbial or fermentation-derived vesicles — produced from bacterial or yeast culture. Less common, but a legitimate cosmetic material with straightforward supply.
• Human cell-derived exosomes and conditioned media — derived from human stem cell culture. Commercially attractive because of the associated clinical narrative, and the most regulated of the three by a wide margin.

On an ingredient list, exosome materials are declared under the INCI name of the source material and its processing, not as "exosome" — you might see a plant callus culture extract, a ferment filtrate, or a similar declaration. As with PDRN, the marketing term and the label term are different words, and the gap between them is where compliance problems start.

Why Brands Are Developing Exosome Products

Exosome skincare occupies the position PDRN held a few years earlier: a clinic-adjacent ingredient with high consumer awareness and a premium price ceiling. Brands come to it for three reasons.

• Price positioning. The ingredient supports a genuinely premium price point, which changes the economics of a small launch.
• Technical credibility. A single exosome hero product signals that a brand is serious about formulation, which lifts the perceived quality of a conventional range around it.
• Clinic and professional channels. Exosome products sell well into spas, clinics and professional channels where the buyer is comfortable with technical language.

The risk is the mirror image of the opportunity. Exosome is the category where marketing claims most often outrun what the product can legally say, and where enforcement attention is highest. A brand that treats it as a normal active and writes normal claims will usually be fine. A brand that borrows language from clinical exosome research will not.

Product Formats We Can Develop

Exosome materials are supplied as aqueous dispersions and are sensitive to heat, shear and some preservative systems, which narrows the format list.

• Serums and ampoules — the primary format, and the one the raw material is designed for. See Korean serum and ampoule manufacturing.
• Two-part and freeze-dried systems — a lyophilised powder reconstituted with an activator at the point of use. Protects the material and creates a strong premium ritual, at meaningfully higher component and filling cost.
• Creams and emulsions — workable with cool-phase addition and a compatible emulsifier system. Covered under moisturiser and cream development in Korea.
• Sheet masks and essences — suited to the material and popular in professional channels. See Korean sheet mask manufacturing.
• Cleansers and rinse-off — technically possible, commercially hard to justify. The contact time does not support the price the ingredient demands.

Developing an Exosome Product: ODM, OEM or Private Label?

For exosome specifically, this decision is entangled with sourcing in a way it is not for most actives — because the raw material you can use depends on where you are selling.

The practical guidance is narrower than for most ingredients. If you sell into a single market and a suitable base exists, private label is efficient. If you sell into two or more regions with different rules — and most brands eventually do — exosome ODM development against your brief is worth the extra cycle, because reformulating for a second market later usually costs more than developing once with both in view.

OEM production in Korea is the route for brands transferring an existing formula. Expect us to ask for the raw material's origin, specification and documentation before quoting. Where that documentation does not exist, the honest answer is that the transfer is really a redevelopment.

Formulation Considerations

Source first, formula second. Fix the source material before any other formulation decision. Every downstream choice — preservative, pH, packaging, claim set — is affected by it, and changing source late means starting over.

Concentration and what it means. Suppliers quote particle counts per millilitre, protein content, or simply a percentage of the supplied dispersion. These are not interchangeable and cannot be compared across suppliers without the underlying specification. Ask what a quoted number measures.

Heat and shear. Vesicles are physically fragile. The material goes in at the end of the process, at low temperature, with gentle mixing. High-shear homogenisation after addition defeats the point of using it.

pH and electrolytes. A near-neutral, low-electrolyte environment is the safest starting point. Strongly acidic systems and high salt loads both risk destabilising the vesicles, and the damage is not visible in the finished product.

Preservation. This is the hardest part. The system must be preserved robustly enough to pass challenge testing, using preservatives that do not disrupt the vesicle membranes. It is the most common reason an exosome formulation needs extra development rounds, and it is why freeze-dried two-part systems exist.

Combinations. Exosome materials sit comfortably with humectants, panthenol, peptides and niacinamide. Combining them with strong surfactants, high alcohol content or exfoliating acids in the same formula is generally counterproductive.

Our Korean cosmetic formulation lab will ask for the destination markets before proposing a route, because on this ingredient the regulatory answer constrains the formulation answer rather than the other way round.

Packaging Considerations

• Airless pump — the default. Minimises oxygen exposure and eliminates finger contact, which matters given the preservation constraints.
• Two-part / lyophilised vial systems — maximum protection and the strongest premium signal. Highest component cost and the longest lead time; specify early.
• Glass ampoules — good protection and strong professional-channel appeal.
• Dropper bottles — consumer-expected in this category, but each use reintroduces air and contact. Only with a preservative system validated for it.
• Sachets for masks — a barrier laminate is required.

Component lead times on two-part systems routinely exceed the formulation timeline, so we qualify components through Korean cosmetic packaging sourcing in parallel with development rather than after it.

Claims and Regulatory Notes by Market

This is the section to read twice. Orientation only — not a compliance opinion.

European Union. Annex II of Regulation (EC) No 1223/2009 prohibits cells, tissues and products of human origin in cosmetic products. Human stem cell-derived exosomes and human cell conditioned media are therefore not usable in cosmetics placed on the EU market, regardless of purity or processing. Plant-derived and microbial-derived materials are assessed on their own merits like any other ingredient, subject to the usual Product Information File, safety assessment, Responsible Person and CPNP notification requirements.

United States. There is no FDA-approved exosome product, and the FDA has issued a public safety notification on exosome products directed at clinics marketing them. That notification concerns unapproved biological products rather than topical cosmetics, but it sets the enforcement context. For a topical cosmetic the governing question is the usual one: a product intended to affect the structure or function of the body is a drug, whatever the label says. Regenerative, healing and cell-repair language is exactly what moves an exosome cosmetic across that line. MoCRA registration, listing and safety substantiation obligations apply as they do to any imported cosmetic.

Korea. Cosmetics are governed by the Cosmetics Act under the MFDS. Korea permits human cell and tissue culture media in cosmetics under a dedicated safety standard that imposes donor screening, testing and documentation requirements — which is one reason materials of this type are more visible in the Korean domestic market than in the EU. A product made legally for Korea using such a material is not automatically exportable, and this is the specific trap this page exists to flag.

Other markets. Rules on human-derived material vary and several markets follow the EU position. Confirm before selecting a source rather than after.

See exporting cosmetics from Korea for the documentation we supply and where responsibility passes to your importer or responsible person.

MOQ and Development Timeline

We do not publish minimum order figures. On exosome projects the number is driven less by fill volume than by the two factors below, which is why a generic figure would mislead.

• Raw material. Exosome materials are expensive and carry their own supplier minimums. On a small run the raw material minimum, not the filling minimum, is usually what sets the floor.
• Packaging. A two-part or lyophilised system has component minimums well above a standard bottle, and longer lead times.
• Route. Private label from a qualified base starts lower than ODM development.
• Markets. Each destination adds labelling, registration and documentation cost, which changes whether a small first run makes sense at all.

How cosmetic MOQ is actually determined sets out how these interact and what to adjust if the first quote is above budget. On timeline, expect exosome development to run longer than a comparable serum, with the additional time spent on preservation and stability rather than on sensory work.

Frequently Asked Questions

Are plant exosomes and human stem cell exosomes interchangeable?

No, in three separate ways: they are different materials, they carry different documentation and supply constraints, and they have different regulatory status. The EU prohibits products of human origin in cosmetics, so for any brand selling in Europe they are not substitutable at all. Decide the source before development starts.

Can I sell a human cell-derived exosome cosmetic in Europe?

No. Annex II of the EU Cosmetics Regulation prohibits cells, tissues and products of human origin in cosmetic products. A product legally manufactured and sold in Korea using such a material cannot be placed on the EU market on that basis. Plant-derived and microbial-derived alternatives are the route for European distribution.

What will exosome appear as on my ingredient list?

Under the INCI name of the source material and its processing — typically a plant callus culture extract, a ferment filtrate or a comparable declaration — not as "exosome". We confirm the exact declaration for your destination market before artwork is finalised.

Why is preservation the hard part of an exosome formula?

The preservative system has to be strong enough to pass challenge testing while using materials that do not disrupt the vesicles it is protecting. Those two requirements pull in opposite directions. It is the most common reason an exosome project needs additional development rounds, and it is the reason freeze-dried two-part systems exist as a format.

Can I combine exosomes with PDRN in one product?

Technically yes, and brands ask often. Commercially it is usually the wrong call: cost rises steeply, preservation and stability work compounds, and substantiating what each active contributes becomes harder rather than easier. We generally recommend one lead active with a supporting complex — see PDRN serum and ampoule development if you are weighing the two.

Should my first exosome product be private label or ODM?

If you sell into one market and a qualified base exists there, private label is efficient and fast. If you sell into two or more regions, ODM is usually cheaper overall, because selecting the source material once against all your destination markets avoids reformulating later. The number of markets, not the size of the brand, is what decides this.

This page is general information for manufacturing planning. It is not legal or regulatory advice, it has no legal effect, and no rights can be derived from it. Requirements change by market and over time — before acting on anything here, confirm the current position with the authority concerned or with qualified counsel.